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Background: Current evidence suggests a central role for autophagy in many neurodegenerative diseases including
Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Furthermore, it is
well admitted that inflammation contributes to the progression of these diseases. Interestingly, crosstalks between
autophagy and inflammation have been reported in vitro and at the peripheral level such as in Crohn’s disease.
However, the impact of systemic inflammation on autophagic components in the brain remains to be documented.
Therefore, this study monitored autophagy markers after acute and chronic lipopolysaccharide (LPS)-induced
inflammatory stress in mice.
Results: We showed that acute inflammation, 24 h post-intraperitoneal 10 mg/kg LPS, substantially increased cytokine
production (Interleukin(IL)-1β, Tumor necrosis factor (TNF)-α and IL-6), decreased the levels of autophagy markers
(Beclin-1, p62 and LC3 II) and reduced p70S6K activation in cortex and hippocampus. In hippocampus, IL-1β levels
and LC3 II expression were positively and highly correlated and a negative correlation was noted between TNF-α
levels and p70S6K activation. Chronic inflammation by injection of 0.5 mg/kg LPS every three days during three
months led to a moderate IL-1β production and decreased TNF-α levels. Interestingly, Beclin-1 and LC3 II levels
decreased while those of p62 increased. Cortical IL-1β levels positively correlated with Beclin-1 and LC3 II and on
the contrary inversely correlated with p62.
Conclusion: The present study is the first showing links between IL-1β-mediated inflammation and autophagy in
the brain. It could open to new therapeutic strategies in brain diseases where regulation impairment of inflammation
and autophagy progress with the severity of diseases.
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Autophagy is a major catabolic pathway in eukaryotic cells
and is responsible for the degradation in the lysosome of
long-lived proteins and altered or unwanted organelles.
Autophagy not only plays a crucial role in the maintaining
of cell homeostasis and protein quality control but also
constitutes an adaptive response to nutritional stress and
protects the cells against microbial and viral pathogens* Correspondence: arnaudfrancois85@gmail.com
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unless otherwise stated.and damaged structures. The molecular mechanisms
controlling autophagy processes are complex. The mam-
malian target of rapamycin (mTOR) is an S/T kinase
playing a central role in the control of autophagy [1-5].
However autophagy can be induced in mTOR-independent
manners, in that cases it involves inositol, calcium, 5’-ad-
enosine monophosphate-activated protein kinase (AMPK),
Jun kinase (JNK)-beclin-1 complex and Sirtiun-1 [6-11].
Through this regulation, autophagy controls cell metabol-
ism, apoptosis, protein secretion and cell-mediated immune
responses [12-16]. The role of autophagy in inflammatory
diseases was initially established through genome-wide
association studies (GWAS) showing that polymorphismsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Cortical and hippocampus cytokine levels in mice
treated with 1 mg/kg of LPS
Cortex Hippocampus
NaCl LPS NaCl LPS
IL-1β 28.07 ± 7.53 35.05 ± 15.55 62.65 ± 16.35 40.4 ± 14.80
TNF-α 3.57 ± 1.30 2.83 ± 0.80 6.53 ± 1.42 1.47 ± 0.62
IL-6 3.06 ± 1.02 6.07 ± 1.16 3.23 ± 0.88 3.05 ± 0.96
Levels of IL-1β, TNF-α and IL-6 measured by ELISA in cortex and hippocampus
of 3-months old mice treated with one i.p. injection of LPS at 1 mg/kg or saline
(0.9% NaCl) and sacrificed after 3 hours. Cytokine levels are expressed in pg/mg
of protein. Results are ± SEM of 3 mice per group. ND: not detectable, under the
limit of detection.
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http://www.molecularbrain.com/content/7/1/56in autophagy-associated genes, such as ATG16L1 and
IRGM, are linked to Crohn’s disease, the well-known
inflammatory bowel disease [17-20]. In addition, poly-
morphisms in autophagy-associated genes have been
associated with other inflammatory diseases such as
systemic lupus erythematosus [21], asthma [22] and
rheumatoid arthritis [23]. Besides, autophagy has been
recognized to have an anti-inflammatory action since
the production of interleukine (IL)-1β and IL-18 was
increased in the absence of functional ATG16L1 (a key
protein of the ubiquitin-like conjugation system Atg5-
Atg12 ~ Atg16) in a mouse model of Crohn’s disease
[24]. Several convergent reports showed that autophagy
interferes with inflammasome (complex involved in IL-
1β maturation) activation by targeting ubiquitinated
aggregates of inflammasome components for destruction
[25-28]. Conversely, altered proteostasis has been shown
recently to activate inflammasome [29]. In addition,
NF-κB signalling pathway has been demonstrated to be
involved in the induction of autophagy [30,31] and the
pro-inflammatory cytokines IL-1β, TNF-α and IFN-γ were
shown to activate autophagy under infectious stimuli
[32,33] contrary to IL-4 and IL-13 [34].
The interconnections between autophagy and inflam-
mation were mainly described at peripheral level in
particular in inflammatory bowel diseases [35], type 2
diabete [36], cardiac disorders [37], cystic fibrosis [38].
However, such interconnections remain to be investigated
in the central nervous system (CNS) as autophagy alter-
ations and inflammation are also two components of
neurodegenerative disorders such as Parkinson’s disease
(PD), Alzheimer’s disease (AD), Huntington’s disease
(HD), Amyotrophic Lateral Sclerocis (ALS) [39].
Here, we investigated the impact of an inflammatory
reaction on the autophagic process in the CNS in vivo.
Neuroinflammation was triggered by intraperitoneal lipo-
polysaccharide (LPS) injection in mice as previously
described in rodents [40-44]. We showed that according
to the inflammatory stress severity (acute versus chronic),
neuroinflammation differently altered autophagy in the
brain underlying a potential role of cortical IL-1β in
the alterations of autophagy in the CNS. These find-
ings reported for the first time relationships between
inflammation and autophagy in CNS and could open
to new therapeutic strategies in brain diseases where
regulation impairment of inflammation and autophagy
progress with the severity of diseases.
Results
As indicated, we first studied the impact of a peripheral
acute inflammatory stress induced by LPS on cerebral
autophagy in wild-type B6C3F1 mice. Preliminary exper-
iments were performed using 2 doses of LPS: either one
i.p. injection at 1 mg/kg, and sacrifice 3 h after or 3 i.p.injections at 3 mg/kg per 24 h before sacrifice. However,
no statistically significant production of IL-1β, TNF-α
and IL-6 was measured compared to saline group mice
(Tables 1 and 2). Consequently, we used a higher LPS
dose of 10 mg/kg, 3 i.p injections per 24 h, in order to
trigger relevant inflammatory response in our experimen-
tal settings. This relatively high dose has been previously
reported, by other authors, to be lethal 48 h after LPS
injection [45]. In our study, animals received 1, 2 or 3 i.p
injections and were sacrificed 24 h after LPS injections.
In these conditions, no mortality was observed.
Pro-inflammatory cytokine levels after acute LPS-induced
inflammatory stress
In saline group mice, no statistically significant variations
of cytokine levels were observed in cortex and hippo-
campus whatever the design of treatment (see Additional
file 1: Table S1 and S2). Therefore, results for NaCl
correspond to the mean in each figure.
After 24 h, two or three injections of LPS at a dose of
10 mg/kg increased IL-1β, TNF-α and IL-6 levels in the
cortex and in the hippocampus (Figure 1). Cortical IL-1β
levels were 5.6- and 13.5-fold higher compared to the
corresponding vehicle-injected mice with two and three
injections, respectively (Figure 1A). Hippocampal IL-1β
levels were 3 and 5 times higher (Figure 1D). Cortical
TNF-α levels increased by 131 and 17.5 times with two
or three injections, respectively. Hippocampal TNF-α
levels were 30 and 8 times higher (Figure 1B and E). For
IL-6, cortical levels were 121 or 254 times higher with
two or three injections, respectively and hippocampal levels
were 40 or 212 times higher, compared to those measured
in vehicle-treated mice (Figure 1C and F). Unlike IL-1β
and TNF-α, IL-6 levels were significantly increased in
the cortex from 6 h (148-fold) and from 4 h in the
hippocampus (50-fold).
Changes in autophagic factors after acute LPS-induced
inflammatory stress
As for inflammatory markers, no statistically significant
variations of autophagic markers were observed in cortex
Table 2 Cortical and hippocampus cytokine levels in mice
treated with 3 mg/kg of LPS
Cortex Hippocampus
NaCl LPS NaCl LPS
IL-1β 23.94 ± 6.71 18.05 ± 1.44 35.1 ± 1.22 49.32 ± 8.25
TNF-α 1.24 ± 0.29 1.78 ± 0.10 1.62 ± 0.20 1.67 ± 0.56
IL-6 3.83 ± 0.95 3.56 ± 0.24 5.33 ± 0.26 3.87 ± 0.08
Levels of IL-1β, TNF-α and IL-6 measured by ELISA in cortex and hippocampus
of 3-months old mice treated with 3 i.p. injections of LPS at 3 mg/kg or saline
(0.9% NaCl) per 24 h before sacrifice. Cytokine levels are expressed in pg/mg
of protein. Results are ± SEM of 3 mice per group.
Figure 1 Pro-inflammatory cytokine levels after acute LPS-induced inflam
and hippocampus (D, E, F, respectively) of mice treated with a single ( ) or tw
NaCl) were measured by ELISA assay. Mice were sacrificed 2, 4, 6 or 12 h after a
expressed in pg/mg protein. Results are mean ± SEM for 6 mice in each group
group by Kruskal-Wallis test with a Dunns multiple comparison test.
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saline-injected group mice (see Additional file 1: Table S3
and S4). Therefore, results for NaCl correspond to the
mean in each panel of Figure 2.
To determine whether autophagy changes occured
after a peripheral acute inflammatory stress, Beclin-1,
p62, LC3 I and LC3 II were investigated. Beclin-1 is a key
component of the class III PI3K (Phosphatidylinositide
3-kinases) complex which is involved in the initiation
of autophagosome formation [46]; p62 is an autophagic
receptor which recognizes ubiquitinylated proteins and
interacts with LC3 II at the forming autophagosomematory stress. IL-1β, TNF-α and IL-6 levels in cortex (A, B, C, respectively)
o ( ) or three ( ) i.p. injections of LPS at 10 mg/kg or vehicle (0.9%
single injection or 24 h after two or three injections. Cytokine levels were
. *p < 0.05, **p < 0.01, ***p < 0.001 compared to 0.9% NaCl-injected mouse
Figure 2 Changes in autophagic factors after acute LPS-induced inflammatory stress. Representative immunoblots showed the immunoreactivity
of Beclin-1 (A), p62 (B) LC3 II (C) in cortex and Beclin-1 (D), p62 (E) LC3 II (F) in hippocampus from mice treated with a single ( ) or two ( ) or three
( ) i.p. injections of LPS at 10 mg/kg or vehicle (0.9% NaCl). Mice were sacrificed 2, 4, 6 or 12 h after a single injection and 24 h after two and three
injections. Semi-quantitative analysis of immunoblot was performed using Gene Tools software (Syngene, Ozyme France). The immunoreactivity of
protein was normalized to β-tubulin immunoreactivity. The results are expressed as arbitrary units (% of 0.9% NaCl-injected mice group set at 100%).
Results are mean ± SEM for 6 mice in each group. *p < 0.05, **p < 0.01 compared to 0.9% NaCl-injected mouse group by Kruskal-Wallis test with a
Dunns multiple comparison test.
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which, when is conjugated to phosphatidylethanolamine
(through an ubiquitin-like conjugation reaction) of the
membrane of autophagosome, produces LC3 II form, a
useful marker of autophagic vacuoles [47].Beclin-1 expression was affected only in hippocampus
with a decrease by 52% after 12 h post-injection (Figure 2A
and D). A higher inflammatory stress with two or
three LPS injections did not significantly change
Beclin-1 expression (Figure 2D).
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by 71% after 4 h and return to basal line after 6 and
12 h in the hippocampus (Figure 2E). No changes in
p62 levels were observed in the cortex after a single
injection (Figure 2B). On the contrary, a decrease in
p62 levels of 18-20% with two injections and of 55-60%
with three injections in both cortical and hippocampal
area were observed (Figure 2B and E).
For LC3 marker, any change was observed for LC3 I
both in cortex and hippocampus regardless the time
post- LPS injection. However, LC3 II significantly decreased
at 12 h in the cortex (45%), at 6 h in the hippocampus
(56.5%) and at 24 h after two or three injections (45-58%)
in both areas (Figure 2C and F).
Ultrastructure of cells in cortex and hippocampus after
systemic LPS administration (two injections per 24 h)
was similar to control mice with normal morphology of
the mitochondria and the nucleus with evenly distributed
chromatin is visible. Cytoplasm is rich in ribosomes and
polyribosomes. No accumulation of vesicles was observed
in cortex and in hippocampus (Figures 3 and 4).
Activation of mTOR signalling pathway after acute
LPS-induced inflammatory stress
mTOR activation leads to phosphorylation of various
substrates, in particular p70S6K at T389, a ribosomal S6
kinase involved in ribogenesis [48,49]. Furthermore, mTOR
negatively regulates autophagy in several experimental
models.
No modification of the mTOR activation was observed
after an acute LPS stress (Figure 5A and B). However,
the p70S6K activation decreased in time-dependent
manner and significantly from 12 h in the cortex (46%)
and from 4 h in the hippocampus (46%) after one
10 mg/kg LPS injection (Figure 5C and D). With two and
three injections of LPS per 24 h, the p70S6K activation
decreased in both brain areas (24-48%). No statistically
significant variations of the mTOR and p70S6K activation
were observed in cortex and in hippocampus whatever the
design of treatment in saline-injected group mice (see
Additional file 1: Table S3 and S4). Therefore, results for
NaCl correspond to the mean in each panel of Figure 5.
Correlations between cytokine levels and expression of
autophagic markers after acute LPS-induced inflammatory
stress
In our experimental conditions, acute LPS treatment
stimulated cytokine production (IL-1β, TNF-α and IL-6),
decreased autophagic marker expressions and p70S6K
activation without immediate cortical or hippocampal
tissue damage as shown by TEM. Spearman correlations
were performed between inflammatory and autophagic
parameters. In cortex, a positive correlation between
IL-6 levels and p70S6K expression was found (rho = 0.88;p = 0.03; n = 6 mice) at 12 h after a single LPS injection.
In hippocampus and after two LPS injections per 24 h,
two correlations were noted one between IL-1β levels
and LC3 II expression (rho = 0.94; p = 0.01; n = 6 mice)
and a second between TNF-α levels and p70S6K expression
(rho = −0.88; p = 0.03; n = 6 mice).
In this first part, an acute peripheral inflammatory
stress affected the cerebral autophagy with a positive
correlation between LC3 II and IL-1β levels after two
10 mg/kg LPS injections per 24 h. Moreover, p70S6K
expression significantly decreased and the levels of
p70S6K were positively correlated to IL-6 levels in the
cortex at 12 h and negatively to TNF-α levels in the
hippocampus at 24 h with two i.p. LPS injections. In
parallel, we also wanted to study the impact of a chronic
inflammatory stress in autophagy. Three months old mice
received an i.p. dose of 0.5 mg/kg of LPS every 3 days for
3 months. This treatment did not affect the life expectancy
of mice compared to control mice (0.9% NaCl as vehicle).
The average weight was 31.44 ± 5.63 and 34.53 ± 4.75 mg
for control and LPS-treated mice, respectively.
Pro-inflammatory cytokine levels after chronic LPS-induced
inflammatory stress
After 3 months of treatment, IL-1β levels significantly
increased in cortex (495%) and in hippocampus (367%)
compared to control mice (Figure 6A). Surprisingly, TNF-
α levels decreased in both brain areas: 79% in cortex and
63% in hippocampus (Figure 6B). For IL-6, no difference
was observed in LPS-treated mice versus control mice
(Figure 6C).
Changes in autophagy markers after chronic LPS-induced
inflammatory stress
Chronic LPS-induced inflammatory stress decreased
Beclin-1 by 24% and 32% in cortex and hippocampus,
respectively (Figure 7A). On the contrary, a robust
increase of p62 expression was observed in both areas:
455% in cortex and 208% in hippocampus (Figure 7B). A
significant decrease of LC3 II expression was observed
in both areas (37.5% in cortex and 45% in hippocampus)
without changes in LC3 I levels (Figure 7C).
Similarly to what was observed after acute LPS-
induced inflammatory stress, TEM showed that chronic
LPS-induced inflammatory stress did not cause major
morphological tissue alterations. At the cellular level,
mitochondria appeared with a normal shape without
alteration and no vacuole accumulations were observed
in cortex and in hippocampus (Figure 8).
Activation of mTOR signaling pathway after chronic
LPS-induced inflammatory stress
Similarly to acute LPS-induced inflammatory stress, the
mTOR activation was not modified (Figure 9A). However,
Figure 3 Ultrastructure of cortex after acute LPS-induced inflammation. TEM cortical images of 0.9% NaCl-injected mice (A and B) and
10 mg/kg LPS-treated mice (2 injections per 24 h, images C and D). No alteration of tissue integrity was observed in low magnification images
(A and C), myelin rounded axons marked with white arrow. Images B and D represent magnified region of interest of the white square in A and C,
respectively. In these magnified images, mitochondria appeared with intact cristae (mt), endoplasmic reticulum (ER) was present with ribosomes and
lysosomes (L) were observed. Five sections in each area (cortex and hippocampus) were observed for each mouse brain.
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(75%) and hippocampus (74%) (Figure 9B).
Correlations between levels of cytokine and autophagic
markers after chronic LPS treatment
Chronic LPS treatment induced IL-1β production asso-
ciated with changes of autophagic marker expressions
and a great decrease of p70S6K activation without mTOR
activation and without tissue morphological alterations.
Interestingly, Spearman analysis of data from LPS-treated
mice revealed two positive correlations between cortical
IL-1β and Beclin-1 and between IL-1β and LC3 II levels.
Furthermore, a negative correlation between IL-1β and
p62 levels was observed (Table 3). In this LPS mouse
group, only IL-1β would control cortical autophagy.
Another interesting correlation revealed that levels of
beclin-1 expression were negatively correlated with those
of p62 (rho = −0.88, p = 0.03). This last correlation would
reinforce that the cortical autophagic flux would beinduced after a chronic and peripheral LPS treatment.
However, any correlation was observed in hippocampus.
Discussion
Alteration of autophagy and excessive inflammatory
response are two hallmarks common to various brain
diseases such as AD, PD, HD, ALS [13,39]. However,
the relationships between these two defense mechanisms
of the body remain unknown in the CNS. Recently, we
showed in vitro that IL-1β was involved in the acidic
vesicle accumulation in microglia contrary to amyloid
peptide [50]. The current study therefore aimed at deter-
mining whether an inflammatory reaction could modulate
the autophagic process in the CNS.
The i.p. injection of LPS is extensively used to induce
brain inflammation [40,41,51]. Several studies showed
that treatment of mice with LPS induced a central inflam-
matory response associated with microglial activation,
immunomodulatory effects of astrocytes, cyclo-oxygenase-
Figure 4 Ultrastructure of hippocampus after acute LPS-induced inflammation. TEM hippocampal images of 0.9% NaCl-injected mice (A and B)
and 10 mg/kg LPS-treated mice (2 injections per 24 h, images C and D). No alteration of tissue integrity was observed in low magnification images
(A and C). Images b and d represent magnified region of interest of white square in a and c, respectively. In these magnified images, mitochondria
appeared with intact cristae (mt), endoplasmic reticulum (ER) was present with ribosomes, myelin rounded axons marked with white arrow and
lysosomes (L) were observed. Five sections in each area (cortex and hippocampus) were observed for each mouse brain.
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productions [41,42,52-55].
However there are various regimens followed in mice.
Among the acute treatments, the most frequently encoun-
tered are i.p. LPS injection of 0.5, 1 or 5 mg/kg and
sacrifice of animals after one hour to ten days. In that
issue, several studies only reported the transcriptional
analysis of cytokines, in particular IL-1β, IL-6 and
TNF-α in brain regions, showing an increase in mRNA
expression of these cytokines in hippocampus, choroid
plexus [51,56-58]. Here, we used a higher dose (10 mg/kg)
because lower LPS doses (i.e. single dose of 1 mg/kg
or three doses of 3 mg/kg per 24 h) failed to detect
significant increases in cytokine production in the
mouse brains by using ELISA as previously reported
[59]. In the present study, brain inflammatory response
was reflected by a great increase in IL-6 levels started at
4 h in hippocampus and 6 h in cortex after a singleinjection while levels of IL-1β and TNF-α increased after
two or three LPS injections per 24 h.
For the chronic LPS treatment, some authors included
in their experimental design a group of mice received a
single dose of LPS at 5 mg/kg or 10 mg/kg and sacrificed
after 1, 3 or 10 months [41,54]. Here, 0.5 mg/kg LPS
was i.p. injected every three days during three months.
Other authors chose twice injections per week for
6 weeks at a dose of 0.5 mg/kg in 4-month-old 3xTg-AD
transgenic Alzheimer mouse model [60]. In last study,
the monitoring of mRNA expression of IL-1β, IL-6 and
TNF-α showed that IL-1β levels were markedly increased
in the brains of LPS-treated mice. However, IL-6 and
TNF-α expression levels were not significantly altered
by LPS treatment. In our experimental conditions,
chronically LPS-treated wild-type mice displayed a
significant increase in IL-1β whereas TNF-α levels
significantly decreased. Therefore, IL-1β could be
Figure 5 Activation of the mTOR signalling pathway after acute LPS treatment. Representative immunoblots showed the immunoreactivity
of mTOR, PS2448-mTOR, p70S6K and PT389-p70S6K in cortex (A and C) and in hippocampus (B and D) from treated-mice with a single ( ) or two
( ) or three ( ) injections in i.p of LPS at 10 mg/kg or control (0.9% NaCl). Mice were sacrificed 2, 4, 6 or 12 h after a single injection and 24 h
after two and three injections. Semi-quantitative analysis of immunoblot was performed using Gene Tools software (Syngene, Ozyme France). The
immunoreactivity of protein was normalized to β-tubulin immunoreactivity. The results are expressed as arbitrary units (% of 0.9% NaCl-injected mice
group set at 100%). Results are mean ± SEM for 6 mice in each group. *p < 0.01 compared to 0.9% NaCl-injected mouse group by Kruskal-Wallis test
with a Dunns multiple comparison test.
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matory response induced by peripheral LPS during
3 months. The decrease of TNF-α levels was also observed
in brain, liver and serum after a long term time course of
single 5 mg/kg LPS injection [54]. For this higher LPS
dose, authors demonstrated a role of TNF receptors
(TNFR) since in TNFR KO mouse models, LPS-induced
TNF-α production was totally inhibited, suggesting apotential downregultion of these receptors in our experi-
mental design. One may also propose that this decrease
in TNF-α levels could be due to a modification of TNF-
α converting enzyme (TACE) activity, also known as
ADAM17 (a disintegrin and metalloprotease-family) and
involved in the cleavage of TNF-α precursor to produce
mature TNF-α [61]. In accordance with these data, we
previously demonstrated that at 18 months of age,
Figure 6 Pro-inflammatory cytokine levels after chronic LPS-induced inflammatory stress. IL1-β (A), TNF-α (B) and IL-6 (C) levels in cortex
(CO) and hippocampus (HI) from LPS-treated mice (0.5 mg/kg of LPS every 3 days for 3 months) or control (0.9% NaCl every 3 days for 3 months)
by using ELISA assay. Treatment started at 3 months and mice were sacrificed at 6 months of age. Cytokine levels were expressed in pg/mg protein.
Results are mean ± SEM for 6 mice in each group. **p < 0.01, ***p < 0.001 compared to control mice by a Mann–Whitney test.
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TNF-α production [62].
Furthermore, the immuno-tolerance induced by chronic
LPS injections could explain the decrease of TNF-α rate
in cortex and in hippocampus and maintain a significant
higher level of IL-1β. Indeed, it is well established that a
first LPS exposure induced an overproduction of cytokines
following a modification of gene expression in monocyte/
macrophage becoming refractory to secrete some cyto-
kines like TNF-α [48,63,64].
Despite this inflammatory response, normal tissue
morphology and cell integrity were preserved in both
acute and chronic LPS treatment. No signs of cellular
damage were visible by TEM after both acute and chronic
treatments. Authors showed that acute 1 mg/kg of LPS
injection induced no neuronal death (negative Fluorojade
B neurons and negative TUNEL neurons) and no ruptureFigure 7 Changes in autophagy markers after chronic LPS-induced in
immunoreactivity of Beclin-1 (A), p62 (B) and LC3 II (C) in cortex and hipp
3 months) or control (0.9% NaCl every 3 days for 3 months). Treatment starte
were quantified by using Gene Tools software (Syngene, Ozyme France). Data
The results are expressed as arbitrary units (% expression of 0.9% NaCl-treated
*p < 0.05, **p < 0.01 compared to control mice by Mann–Whitney test.of blood brain barrier (BBB) [52,65]. In addition, mainten-
ance of the mitochondrial architecture critically depends
on the induction of autophagy which is essential for
regenerating astrocyte mitochondrial networks during
inflammation [66]. But ultrastructure of a neuronal cell
in the hippocampus 48 h after 1 mg/kg LPS administration
showed shrunken and dark cytoplasm, deep invagination of
the nuclear envelope into the nucleoplasm and swelling
of some mitochondria [51].
The monitoring of autophagy markers, including
Beclin-1, p62 and LC3, in mouse brains after systemic
LPS-induced inflammatory stress, has never been con-
ducted before. Only two papers described an increased
expression of lysosomal cysteine proteases, cathepsins
(Cat) C and B [51,56]. Cat C expression was detected
in neurons of cerebral cortex 6 h after 5 mg/kg LPS i.p. in-
jection and 24 h later, Cat C expression was also detectedflammatory stress. Representative immunoblots showed the
ocampus from LPS-treated mice (0.5 mg/kg of LPS every 3 days for
d at 3 months and mice were sacrificed at 6 months of age. Densities
of each protein were reported to data of the corresponding β-tubulin.
mice set at 100%). Results are mean ± SEM for 6 mice in each group.
Figure 8 Ultrastructure of cortex and hippocampus after chronic LPS-induced inflammatory stress. TEM was performed in LPS-treated and control
mice (n = 3 in each group) in cortex (A and B) and in hippocampus (C and D). Low magnification image of cortex (A) showed a regular distribution of
axons (ax) and microtubule filament inside. Image d represent magnified region of interest showed in the white square in C. The endoplasmic reticulum
(ER) marked with white arrow (B and D) carried ribosomes without abnormalities. Mitochondria (mt) have intact cristae, lysosomes (L) were observed and
synapses with pre-synaptic vesicles are marked by (*). Five sections in each area (cortex and hippocampus) were observed for each mouse brain.
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The duration of induced Cat C expression in neurons and
in microglial cells was ten days and three days, respect-
ively by using in situ hybridation (ISH) and immunohisto-
chemical staining (IHC) [56]. An immunocytochemical
analysis of the subcellular localisation of Cat B using post-
embedding immunogold methods showed that, 48 h after
systemic 1 mg/kg LPS administration, Cat B was translo-
cated from lysosomes to the cytosol and autophagic vacu-
oles and was also found in the membrane of mitochondria
in the hippocampal area.
Our study showed that acute 10 mg/kg LPS treatment
induced autophagy early changes in the hippocampus
with increased p62 and decreased LC3 II 4 h after injection
evolving towards a decrease in the three parameters
(Beclin-1, p62 and LC3 II) 12 h after injection. In the
cortex, the LC3 II decrease was observed from 12 h. After
24 hr, all markers of autophagy significantly decreased in
the cortex and hippocampus. Interestingly, in hippocam-
pus IL-1β levels were positively and strongly (rho = 0.94)
correlated to LC3 II expression, indicating a role of this
cytokine in LC3 II induction. Several cytokines, includ-
ing IL-1β are well known as autophagy stimulatory mol-
ecules [67-69]. Furthermore, the induction of autophagy
was associated with a great inactivation of p70S6K (orRibosomal S6 Kinase 1) without modification of mTOR
activation. The T389 site of p70S6K is known to be
phosphorylated by the kinase mTOR. However,
extensive research on the regulation of the activity of
p70S6K studies show direct control by the active
Receptor Tyrosine Kinase (RTK)/Phosphoinositide 3-
kinase/Phosphoinositide-dependent kinase-1 (PDK1)
signaling pathway that the phosphorylation site is not
defined yet [48]. In addition, RS6K1 dephosphorylation
was an active process of its regulation by protein phos-
phatase 2 (PP2A) [70,71]. Here, a negative correlation
was observed between p70S6K activation and TNF-α
levels in hippocampus, indicating the negative impact
of LPS-induced sepsis in this kinase linked to diverse
cellular processes, including protein synthesis, mRNA
processing, glucose homeostasis, cell growth and survival.
Other authors showed that an in vivo sepsis not induced
by LPS inhibits mTOR signaling pathways in rat cardiac
muscle and that this defect appeared mediated, either
directly or indirectly, by the endogenous over production
of TNF-α [72].
Based on the results obtained, a differential expression
level of autophagy markers between in cortex and in
hippocampus was mainly observed after one injection
of LPS. Hippocampus responded faster than cortex in
Figure 9 Changes in mTOR and p70S6K activation after chronic LPS-induced inflammatory stress. Representative immunoblots showed
the immunoreactivity of mTOR, PS2448-mTOR, p70S6K, PT389-p70S6K in cortex (A) and in hippocampus (B) from LPS-treated mice (0.5 mg/kg of
LPS every 3 days for 3 months) or control (0.9% NaCl every 3 days for 3 months). Treatment started at 3 months and mice were sacrificed at 6 months
of age. Semi-quantitative analysis of immunoblot was performed using Gene Tools software (Syngene, Ozyme France). The immunoreactivity of protein
was normalized to β-tubulin immunoreactivity. The results are expressed as arbitrary units ((% of 0.9% NaCl-injected mice group set at 100%). Results
are mean ± SEM for 6 mice in each group. **p < 0.01 compared to control mice by a Mann–Whitney test.
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ferences of autophagy levels between these two brain
structures were also observed in rats after various acute
stresses such as hypoxia-ischemia, oxygen and glucose
deprivation or 6-OHDA injection [73-75]. Some authors
showed a differential brain activity after a peripheral
inflammation. It was demonstrated that during sepsis,
the BBB lose its structural integrity allowing the cross
of peripheral cytokines and macrophages in the brain
[76,77]. The brain can be sense peripheral inflammation
through the vagus nerve and the hypothalamic–pituitary–
adrenal axis and influence the brain activity, memory,
plasticity, neurogenesis [78]. These brain-peripheral im-
mune interactions could also explain the differential ex-
pression level of autophagy markers between in cortex
and in hippocampus in our study.Table 3 Correlation between autophagic factors and IL-1β
levels during chronic LPS –induced inflammatory stress
Beclin-1 p62 LC3 II
rho p rho p rho p
IL-1β 0.88 0.03 - 0.88 0.03 0.88 0.03
Spearman correlations were performed between IL-1β and autophagic parameters
measured in the cortex of LPS-treated mice (0.5 mg/kg of LPS every 3 days for
3 months). Treatment started at 3 months and mice were sacrificed at 6 months of
age (n = 6). In table, rho and p values were indicated. The level of significance
was p < 0.05.Although some authors have examined the level of
expression of cathepsins after acute treatment with LPS in
mice, no study has yet been published on the autophagic
changes in long-term chronic treatment with LPS. This
work, however, is very important when taken into consid-
eration the fact that many neurodegenerative diseases are
characterized by disturbances both in the regulation of
inflammation and autophagy. We observed after 3 months
of neuroinflammation induction, an upregulation of p62
coupled to a net decrease in expression of Beclin-1 and
LC3 II. Very interestingly, correlation analysis revealed
that the IL-1β production after chronic LPS treatment
induced autophagic flux. In accordance with our results, it
is known that inflammasome, in particular caspase 1 also
increases autophagic flux [79]. However, a recent study
revealed that inflammatory stimulus in macrophage cell
line and in human macrophages activated autophagy and
decreased production of IL-1β production [26] due to the
degradation of inflammasome complex by autophagy.
This feedback would be necessary to counteract and to
limit the inflammation reaction due to minor insult. In
our in vivo study, this beneficial autophagy feedback could
explain that one LPS injection was not sufficient to mea-
sured significant IL-1β levels in cortex and hippocampus
and required more injections (2 or 3 i.p injections). Inter-
estingly, a chronically administration but not a lower LPS
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against IL-1β production and induce an increase of IL-1β
levels in cortex and in hippocampus.
Regarding p62, results showed negative correlation
between its levels of expression and those of IL-1β. In
other experimental conditions, recent findings showed
that the production and secretion of the proinflammatory
cytokine IL-1β was significantly enhanced in p62−/− mac-
rophages after infection with Legionella pneumophila.
Furthermore, these authors showed that p62 may interact
with nucleotide-binding oligomerization domain-like
receptor (NLR) family, CARD domain-containing 4 and
NLR family, pyrin domain-containing 3 proteins to inhibit
their self-dimerization [80]. However, its self-dimerization
is a necessary step for its degradation during autophagy
[81]. Based on these physical interactions, p62 could accu-
mulate as we observed after a chronic LPS treatment.
Conclusion
An acute and a chronic peripheral inflammatory stress
induced by LPS, in particular, with a persistent IL-1β
production modified cortical and hippocampus autophagic
marker expressions. Chronic inflammatory stress increased
p62 and decreased Beclin-1, LC3 II and p70S6K activation
without changes of the mTOR activation and any mor-
phological tissue alteration. Moreover, IL-1β levels were
positively correlated to Beclin-1 and LC3 II while p62
expression was inversely correlated to IL-1β levels after
chronic neuroinflammation. These findings highlighted
the induction of central autophagy by IL-1β-mediated
inflammation. It is important to note that the rate of
this inflammatory factor remains very moderate, less
than 15 pg/mg protein in both brain regions studied
and therefore this level would be interesting to activate
autophagy in neuroinflammatory diseases including neuro-
degenerative diseases characterized by a great inflammation
and accumulation of autophagosomes in advanced stages.
Methods
Chemical products
Sodium fluoride (NaF), phenylmethylsulfonyl fluoride
(PMSF), protease and phosphatase inhibitor cocktails,
dithiothreitol (DTT), Lipopolysaccharide (LPS), Parafor-
maldehyde (PFA) and all reagent-grade chemicals for
buffers were purchased from Sigma (St Quentin Fallavier,
France); Sodium pentobarbital from CEVA, Animal
Health (Libourne, France); NuPAGE® LDS 4X LDS Sample
Buffer, NuPAGE® Sample Reducing Agent (10X), Novex®
4-20% Tris-glycine Mini gels, NuPAGE® 3-8% Tris-Acetate
gels, Novex® Tris-Glycine SDS Running and NuPAGE®
Tris-Acetate SDS running buffers, NuPAGE® Antioxidant,
Seeblue® Plus2 pre-stained standard, iBlot® Gel Transfer De-
vice (EU), Quant-it® protein assay from Gibco-Invitrogen
(Fisher Bioblock Scientific distributor, Illkirch, France);4X Laemmli sample buffer, 4-15% mini-PROTEAN®
TGX™ gels, Tris-glycine running buffer and Trans-Blot®
Turbo™ Transfer System from Biorad (Marnes-la-Coquette,
France).
For western blot, primary antibodies and secondary
anti-rabbit IgG antibody conjugated with Horseradish
Peroxydase (HRP) were purchased from Cell Signalling
(Ozyme, St Quentin Yvelines, France) excepted p62/
SQMT1 from MBL (CliniSciences distributor, Nanterre,
France), anti-β tubulin from Sigma (St Quentin Fallavier,
France), peroxidase-conjugated anti-mouse IgG from
Amersham Biosciences (Orsay, France), IgG- and protease-
Free Bovine Serum Albumin (BSA) from Jackson
ImmunoResearch Europe Ltd (Interchim distributor,
Montluçon, France).Animals
Adult male and female B6C3F1 mice (3 months, 30.50 ±
0.82 mg in weight) were purchased from Charles River
Laboratories (L’Arbresle, France). The use of animals for
this study has received the approval of the Ethical and
Animal Care Committee at “La direction départementale
de la protection de la population (DDPP)” (registration
number: 06.12). All animal cares and experimental proce-
dures were conducted in conformity with the French Décret
n° 2013–118 1st February 2013 NOR: AGRG1231951D
in accordance with European Community guidelines
(directive 2010/63/UE for the Care and Use of Laboratory
Animals). All efforts were made to minimize animal
suffering, as well as, the number of animals used. The
animals were housed in a conventional state under ad-
equate temperature (23 ± 3°C) and relative humidity
(55 ± 5%) control with a 12/12 h reversed light/dark
cycle, and provided with free access to food and water.Lipopolysaccharide-induced inflammatory stress
LPS (Escherichia coli, serotype 0111:B4) was used to induce
an inflammatory response. Two experimental designs were
performed. First, an acute treatment with LPS intraperi-
toneally (i.p.) injected at a dose of 10 mg/kg dissolved in
sterile-endotoxin-free 0.9% saline vehicle. Control injections
were equivolume vehicle. Mice (6 per group) were sacri-
ficed after 2, 4, 6, 12 h post-injection. Two other groups
received either two or three i.p. LPS injections per 24 h
before sacrifice (n = 6 in each group). Second a chronic
treatment with LPS consisted of an i.p. injection at a dose
of 0.5 mg/kg every three days during three months (6 con-
trols versus 6 LPS mice). For this chronic treatment, mice
were weighted once a week. The dosage of LPS in both
acute and chronic treatments was based on previous stud-
ies of LPS-neurotoxicity [52,54,82]. For scanning electron
microscopy, three mice per group were also included in
this study.
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LPS-treated and control (0.9% saline vehicle) mice were
transcardially perfused with phosphate buffer saline
(154 mM NaCl, 1.54 mM KH2PO4, 2.7 mM Na2H-
PO4.7H2O, pH 7.3) after deep anesthesia with pentobar-
bital (80 mg/kg, i.p.). Brains (6 per group for biochemical
assays) were rapidly removed and dissected on ice. Cortex
and hippocampus were homogenized using 10 up-and-
down strokes of a prechilled Teflon-glass homogenizer in
20 volumes of lysis buffer (25 mM Tris–HCl, 150 mM
NaCl, 1 mM EDTA, pH 7.4) and supplemented with
50 mM NaF, 1 mM PMSF, protease and phosphatase
inhibitor cocktails (50 μL/gr of tissue and 10 μL/mL of
lysis buffer, respectively). Lysates were sonicated and
centrifuged at 15,000 g for 15 min at 4°C. The resulting
supernatants were collected and protein concentrations
were determined using Quant-it® protein assay according to
the manufacturer’s protocol. Samples were stored at −80°C
until ELISA and immunoblotting described below.
Cytokine Enzyme-linked immunosorbent assay (ELISA)
Commercially available ELISA kits were used for measur-
ing mature form of IL-1β (sensitivity: 16 pg/mL), TNF-α
(sensitivity: 4 pg/mL) and IL-6 (sensitivity: 2 pg/mL)
according to the manufacturers’ instructions (BioLegend,
Ozyme distributor, St Quentin Yvelines, France). The
range of analysis was between 31.3-2,000 pg/mL for IL-1β
and 7.8-500 pg/mL for TNF-α and IL-6. Homogenates
from brain tissue (50 mg of tissue/mL) were added in each
well of pre-coated plates and all steps were performed
at room temperature (RT). The enzymatic reaction was
stopped after 15 min incubation with tetramethylbenzi-
dine (TMB) substrate by adding 2 N H2SO4 and the
optical density (OD) was read at 450 nm within 30 min,
using Multiskan® spectrum spectrophotometer. The cyto-
kine levels were then calculated by plotting the OD of
each sample against the standard curve. The intra- and
inter-assay reproducibility was >90%. OD values obtained
for duplicates that differed from the mean by greater
than 10% were not considered for further analysis. For
convenience, all results are expressed in pg/mg protein.
Immunoblotting
Samples (40 μg proteins) were prepared for electrophor-
esis by adding NuPAGE® 4X LDS sample buffer and
NuPAGE® Sample Reducing Agent (10X). Samples were
then heat-denatured at 100°C for 5 min, loaded into
Novex® 4-20% Tris-Glycine mini Gels, run at 150 V for
60 minutes in Novex® Tris-Glycine SDS Running Buffer
and in NuPAGE® 3-8% Tris-Acetate Gels, run at 125 V
for 120 minutes in NuPAGE® Tris-Acetate SDS running
buffer containing NuPAGE antioxidant. Gels were trans-
ferred to nitrocellulose membranes using the iBlot® Dry
blotting system set at 20 V for 7 min. For LC3immunoblot, we used Trans-Blot® Turbo™ Transfer Sys-
tem (25 V, 3 min for 0.2 μm nitrocellulose MISI format)
after protein gel electrophoresis of samples prepared in
4X Laemmli sample buffer and loaded into 4-15% mini-
PROTEAN® TGX™ gels with Tris-glycine SDS running
buffer.
Membranes were washed for 10 min in Tris-buffered
saline/Tween (TBST: 20 mM Tris–HCl, 150 mM NaCl,
pH 7.5, 0.05% Tween 20) and aspecific antigenic sites
were blocked by incubating the membranes in TBST
containing 5% BSA for 2 h.
Blots were incubated with primary antibody in blocking
buffer overnight at 4°C. Antibodies used were rabbit
anti-PS2448-mTOR, anti-total mTOR, anti-PT389-p70S6K,
anti-total p70S6K, anti-Beclin-1, anti-p62, anti-LC3, all at
1:500 dilution factor. Membranes were washed twice
with TBST and then incubated with the HRP-conjugated
secondary anti-rabbit IgG antibody (1:1000), during 1 hour
at RT. Membranes were washed again and exposed to
the chemiluminescence Luminata Forte Western HRP
Substrate (Millipore, Saint-Quentin-en-Yvelines, France)
followed by signal’s capture with the Gbox system (GeneS-
nap software, Syngene, Ozyme distributor). After 2 washes
in TBST, membranes were probed with mouse antibody
against tubulin (1:10000) overnight at 4°C. They were then
washed with TBST, incubated with HRP-conjugated
secondary antibody anti-mouse (1:1000) for 1 h, exposed
to the chemiluminescence Luminata classico substrate
(Millipore, Saint-Quentin-en-Yvelines, France) and signals
were captured. Automatic image analysis software is
supplied with Gene Tools (Syngene, Ozyme distributor).
Ratios protein/tubulin were calculated and showed in the
corresponding figures. Ratios Phospho-protein/total pro-
tein were calculated to evaluate rates of protein activation.
Transmission electron microscopy (TEM)
Three mice in each group were were deeply anesthetized
with pentobarbital (80 mg/kg, i.p.) and transcardially
perfused with phosphate buffer saline (PBS: 154 mM
NaCl, 1.54 mM KH2PO4, 2.7 mM Na2HPO4.7H2O,
pH 7.2) and then with paraformaldehyde (PFA 4%). Brains
were rapidly removed on ice and thin sagittal sections
were isolated and fixed with 3% glutaraldehyde in phos-
phate buffer saline (0.1 M PBS; pH = 7.4) for 2 h at 4°C.
Samples (2 mm3 of tissue in cortex and hippocampus)
were then washed three times (3x10 min) in PBS and then
post-fixed in 1% osmium tetroxyde in PBS for 1 h at 4°C,
processed through a graded acetone series, embedded in
Araldite (Fluka, Buchs, Switzerland) and polymerized
overnight at 60°C. Thin sections (60 nm) were cut with
a diamond knife on Reichert Ultracut S, recovered on
Cu grids and contrasted with uranyl acetate (4%) and
lead citrate and were observed under a JEOL 1010
transmission electron microscope (Jeol Ltd, Tokyo, Japan).
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observed for each mouse brain.
Statistical analysis
For biochemical analysis, results were expressed as
means ± SEM. To compare the two groups of mice in
chronic treatment (control versus LPS mice) a mann-
Withney’s test was used. Data for multiple variable com-
parisons were analyzed by a Kruskal-Wallis test with a
Dunns multiple comparison test. For correlations between
two parameters, we used a Spearman test (GraphPad
Instat, GraphPad Software, San Diego, CA, USA). The
level of significance was p < 0.05.
Additional file
Additional file 1: Table S1. Cortical cytokine levels in saline-treated
mice. Table S2. Hippocampal cytokine levels in saline-treated mice.
Table S3. Changes in cortical autophagic markers and mTOR signalling
pathway in saline-treated mice. Table S4. Changes in hippocampal
autophagic markers and mTOR signalling pathway in saline-treated mice.
Figure S1. Accumulation of autophagic vesicles in murine primary mixed
cell culture.
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